Obesity accompanied by abnormal glucose metabolism
Conditions
Interventions
Treatment group:Using an ultrashort wave therapy device, treat the trunk area. Set the pulse mode and the peak power within the range of 300-500W. Each treatment lasts for 20 minutes. Administer the t
Sponsors
shandong provinvial third hospital
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age is between 20 years and 60 years; (2) Meet any of the following criteria for obesity or overweight: 1) 28 kg/m^2 = 90 cm for men and >= 85 cm for women; (3) Have impaired fasting glucose with a fasting blood glucose level greater than 6.1 mmol/L or have type 2 diabetes with a glycated hemoglobin level less than 7.5% and have not taken any hypoglycemic drugs; (4) Understand the research procedures and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with allergic constitution or a history of gastrointestinal diseases within the past two months; 2. In the acute phase of inflammation; 3. Within 4 weeks prior to screening, having received any medication or treatment that might affect the intestinal flora, such as probiotics or antibiotics; 4. Type 1 diabetes, gestational diabetes, or special types of diabetes; 5. Diabetic patients using any hypoglycemic drugs and those with a glycated hemoglobin level > 7.5%; 6. Having experienced acute diabetic complications within 3 months prior to screening or having severe chronic diabetic complications; 7. Complicated with hypertension, polycystic ovary syndrome, hyperlipidemia, and those whose medication dosage is unstable within 8 weeks before enrollment, and the investigator judges that their treatment drug dosage may be adjusted during the study period; 8. With poor blood pressure control, that is, systolic blood pressure (SBP) > 150 mmHg and/or diastolic blood pressure (DBP) > 95 mmHg (patients with SBP 500 mg/dL (5.65 mmol/L) and/or total cholesterol (TC) > 250 mg/dL (6.45 mmol/L); 10. Complicated with hyperthyroidism or hypothyroidism; 11. Having experienced major diseases within 6 months prior to screening, or any situation that the investigator deems may interfere with the test results or having concurrent diseases; 12. With liver diseases, such as cirrhosis, active hepatitis, or ALT and AST levels higher than 2.5 times the upper limit of normal; severe kidney diseases, eGFR < 45 mL/min/1.73 m^2; 13. Within 4 weeks prior to screening or expected to use drugs that may significantly affect weight, blood sugar, and lipid metabolism, such as various weight loss drugs, steroid hormones, immunosuppressants, etc., with metal foreign bodies in the body, implanted devices such as cardiac pacemakers or insulin pumps, etc.; 14. Patients with other mental disorders who cannot cooperate or refuse to cooperate; or other situations deemed unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose,Fasting insulin; | — |
Countries
China
Contacts
Public ContactXinfeng bai
Shandong Provincial Third Hospital
Outcome results
None listed